Jiangsu Hengrui Medicine Co Ltd Cash Flow Conversion Efficiency
Jiangsu Hengrui Medicine Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) has a cash flow conversion efficiency ratio of 0.080x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥4.81 Billion ≈ $703.99 Million USD) by net assets (CN¥60.03 Billion ≈ $8.78 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jiangsu Hengrui Medicine Co Ltd (1999–2024)
Cash flow conversion efficiency of Jiangsu Hengrui Medicine Co Ltd from 1999 to 2024. This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 600276 stock price and chart for real-time trading data and today's change.
Jiangsu Hengrui Medicine Co Ltd Cash Flow Conversion Ratio Explained
Jiangsu Hengrui Medicine Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jiangsu Hengrui Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Hengrui Medicine Co Ltd ranked by their cash flow conversion efficiency. Also see 600276 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ArcelorMittal SA ADR
NYSE:MT
|
0.017x |
|
Sun Life Financial Inc.
TO:SLF
|
0.047x |
|
Ciena Corp
NYSE:CIEN
|
0.090x |
|
eBay Inc
NASDAQ:EBAY
|
0.112x |
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
0.018x |
|
Commerzbank AG
F:ZZMS
|
-0.217x |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
0.124x |
|
Ambev S.A
MX:ABEVN
|
0.075x |
Annual Cash Flow Conversion Efficiency for Jiangsu Hengrui Medicine Co Ltd (1999–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Hengrui Medicine Co Ltd from 1999 to 2024. Review Jiangsu Hengrui Medicine Co Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥46.09 Billion ≈ $6.74 Billion |
CN¥7.42 Billion ≈ $1.09 Billion |
0.161x | -13.55% |
| 2023-12-31 | CN¥41.03 Billion ≈ $6.00 Billion |
CN¥7.64 Billion ≈ $1.12 Billion |
0.186x | +465.54% |
| 2022-12-31 | CN¥38.41 Billion ≈ $5.62 Billion |
CN¥1.27 Billion ≈ $185.15 Million |
0.033x | -72.23% |
| 2021-12-31 | CN¥35.57 Billion ≈ $5.21 Billion |
CN¥4.22 Billion ≈ $617.35 Million |
0.119x | +6.39% |
| 2020-12-31 | CN¥30.79 Billion ≈ $4.51 Billion |
CN¥3.43 Billion ≈ $502.20 Million |
0.111x | -27.17% |
| 2019-12-31 | CN¥24.94 Billion ≈ $3.65 Billion |
CN¥3.82 Billion ≈ $558.52 Million |
0.153x | +9.23% |
| 2018-12-31 | CN¥19.80 Billion ≈ $2.90 Billion |
CN¥2.77 Billion ≈ $405.95 Million |
0.140x | -12.30% |
| 2017-12-31 | CN¥15.94 Billion ≈ $2.33 Billion |
CN¥2.55 Billion ≈ $372.76 Million |
0.160x | -20.66% |
| 2016-12-31 | CN¥12.87 Billion ≈ $1.88 Billion |
CN¥2.59 Billion ≈ $379.38 Million |
0.201x | -8.41% |
| 2015-12-31 | CN¥10.36 Billion ≈ $1.52 Billion |
CN¥2.28 Billion ≈ $333.24 Million |
0.220x | +15.77% |
| 2014-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
CN¥1.57 Billion ≈ $230.37 Million |
0.190x | -7.40% |
| 2013-12-31 | CN¥6.66 Billion ≈ $973.96 Million |
CN¥1.36 Billion ≈ $199.74 Million |
0.205x | +16.46% |
| 2012-12-31 | CN¥5.44 Billion ≈ $796.41 Million |
CN¥958.37 Million ≈ $140.24 Million |
0.176x | +46.20% |
| 2011-12-31 | CN¥4.38 Billion ≈ $640.72 Million |
CN¥527.36 Million ≈ $77.17 Million |
0.120x | +8.44% |
| 2010-12-31 | CN¥3.47 Billion ≈ $508.48 Million |
CN¥385.95 Million ≈ $56.48 Million |
0.111x | -32.59% |
| 2009-12-31 | CN¥2.67 Billion ≈ $389.98 Million |
CN¥439.12 Million ≈ $64.26 Million |
0.165x | +183.99% |
| 2008-12-31 | CN¥2.02 Billion ≈ $296.24 Million |
CN¥117.46 Million ≈ $17.19 Million |
0.058x | -56.71% |
| 2007-12-31 | CN¥1.63 Billion ≈ $238.99 Million |
CN¥218.87 Million ≈ $32.03 Million |
0.134x | -36.72% |
| 2006-12-31 | CN¥1.26 Billion ≈ $183.92 Million |
CN¥266.18 Million ≈ $38.95 Million |
0.212x | +2.98% |
| 2005-12-31 | CN¥1.11 Billion ≈ $162.15 Million |
CN¥227.88 Million ≈ $33.35 Million |
0.206x | -1.99% |
| 2004-12-31 | CN¥998.05 Million ≈ $146.05 Million |
CN¥209.41 Million ≈ $30.64 Million |
0.210x | +38.53% |
| 2003-12-31 | CN¥903.35 Million ≈ $132.19 Million |
CN¥136.82 Million ≈ $20.02 Million |
0.151x | +146.17% |
| 2002-12-31 | CN¥809.97 Million ≈ $118.52 Million |
CN¥49.84 Million ≈ $7.29 Million |
0.062x | +305.99% |
| 2001-12-31 | CN¥757.99 Million ≈ $110.92 Million |
CN¥11.49 Million ≈ $1.68 Million |
0.015x | -48.01% |
| 2000-12-31 | CN¥672.57 Million ≈ $98.42 Million |
CN¥19.61 Million ≈ $2.87 Million |
0.029x | -86.02% |
| 1999-12-31 | CN¥162.54 Million ≈ $23.78 Million |
CN¥33.89 Million ≈ $4.96 Million |
0.208x | -- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more